FI116059B - Analogiförfarande för framställning av ett rekombinantprotein kallat komponent B samt DNA-molekyl, expressionsvektor och värdcell - Google Patents
Analogiförfarande för framställning av ett rekombinantprotein kallat komponent B samt DNA-molekyl, expressionsvektor och värdcell Download PDFInfo
- Publication number
- FI116059B FI116059B FI20040608A FI20040608A FI116059B FI 116059 B FI116059 B FI 116059B FI 20040608 A FI20040608 A FI 20040608A FI 20040608 A FI20040608 A FI 20040608A FI 116059 B FI116059 B FI 116059B
- Authority
- FI
- Finland
- Prior art keywords
- seq
- sequence
- dna
- component
- dna molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (9)
1. Analogiförfarande för framställning av ett som läkemedel användbart . . rekombinantprotein, dess salter, funktionella derivat, för- stadier, vilka i kroppen *. * förvandlas tili B-komponent, aktiva fraktioner eller blandningar av dessa, vilket ’ ‘; rekombinant protein är försett med B-komponentaktivitet och innehäller peptidsekvensen ;;; SEKV. ID NO:l, kännetecknat därav, att enligt förfarandet odlas en värdcell, vilken ’ * * * * transformerats med en expressionsvektor, vilken innehäller en DNA-molekyl, vilken är • · · en isolerad och renad nukleotidsekvens SEKV. ID NO:2, cDNA som innehäller '*··' nukleotidsekvensen SEKV. ID NO:3, en aktiv mutant av dessa nukleotidsekvenser eller en aktiv fraktion av dessa eller en DNA-sekvens, som kan hybridisera sig med nämnda : nukleotidsekvenser i en hybridisationslösning, vilken innehäller 5xSSC, 0,02% SDS, .* 0,1% lauroylsarkosin och 0,5% blocking-reagens i 42°C eller 50°C och i en sista : : tvättlösning, vilken innehäller 3xSSC, 0,1% SDS, 0, 9, 18, 27 tai 36% urea i 42°C, vilken : ; DNA-molekyl kodar den aminosyrasekvens, som innehäller peptiden SEKV. ID NO:l • _ eller dess aktiva mutant, vilken har samma aktivitet som komponent B. 116059
2. Förfarandet enligt patentkrav 1, kännetecknat därav att en eller flera aminosyror eliminerats eller substituerats med andra aminosyror i mutantpeptidens aminosyra-sekvens eller en eller flera aminosyror tillsatts tili densamma..
3. Förfarandet enligt patentkrav 1, kännetecknat därav att mutanten är ett fusionsproteini, vilket innehäller immunoglobulin.
4. Förfarandet enligt nägot av patentkraven 1, 2 eller 3, kännetecknat därav att rekombinantproteinet tillvaratas frän en transformerad värdcells cell eller ur odlingsmediet.
5. En DNA-molekyl, kännetecknad därav att den är en isolerad och renad nukleotidsekvens SEKV. ID NO:2 eller cDNA, vars sekvens är SEKV. ID NO:3 eller en aktiv mutant av nämnda nukleotidsekvenser eller en aktiv fraktion av dessa eller en DNA-sekvens, vilken hybridiserar sig med nämnda nukleotidsekvenser i en hybridisationslösning, vilken innehäller 5xSSC, 0,02 % SDS, 0,1 % lauroylsarkosin och 0,5% blocking-reagens i 42°C eller 50°C: och i en sista tvättlösning, vilken innehäller 3xSSC, 0,1% SDS och 0, 9, 18, 27 eller 36% urea i 42°C, vilken DNA-sekvens kodar en aminosyrasekvens, vilken innehäller en peptid SEKV. ID NO: 1 eller dess aktiva mutant, vilken har samma aktivitet som komponent B och i vilken en eller flera aminosyror har • eliminerats eller substituerats med andra aminosyror eller en eller flera aminosyror har ^tillsatts tili dennsa sekvens. I!
’ 6. DNA-molekylen enligt patentkrav 5, kännetecknad därav, att den är den isolerade och ’' I renade nukleotidsekvensen SEKV. ID NO:2.
7. DNA-molekylen enligt patentkrav 5, kännetecknad därav, att den bestär av cDNA, som har sekvensen SEKV. ID NO:3. 1 2 En expressionsvektor, kännetecknad därav, att den innehäller en DNA-molekyl enligt ; nägot av patentkraven 5, 6 eller 7. > 2 En värdcell, kännetecknad därav, att den är transformerad med en expressionsvektor , .; enligt patentkrav 8, vilken innehäller en DNA-molekyl enligt patentkrav 5.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM920919A IT1257184B (it) | 1992-12-22 | 1992-12-22 | Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale |
| ITRM920919 | 1992-12-22 | ||
| EP9303645 | 1993-12-21 | ||
| PCT/EP1993/003645 WO1994014959A1 (en) | 1992-12-22 | 1993-12-21 | New protein from urine named component b |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI20040608A FI20040608A (sv) | 2004-04-29 |
| FI116059B true FI116059B (sv) | 2005-09-15 |
Family
ID=11401349
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI953091A FI114478B (sv) | 1992-12-22 | 1995-06-21 | Förfarande för framställning av protein kallat komponent B ur urin |
| FI20040608A FI116059B (sv) | 1992-12-22 | 2004-04-29 | Analogiförfarande för framställning av ett rekombinantprotein kallat komponent B samt DNA-molekyl, expressionsvektor och värdcell |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI953091A FI114478B (sv) | 1992-12-22 | 1995-06-21 | Förfarande för framställning av protein kallat komponent B ur urin |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5908827A (sv) |
| EP (1) | EP0675956B1 (sv) |
| JP (1) | JP3025014B2 (sv) |
| KR (1) | KR100193107B1 (sv) |
| AT (1) | ATE236976T1 (sv) |
| AU (1) | AU690093B2 (sv) |
| CA (1) | CA2151156A1 (sv) |
| DE (1) | DE69332861T2 (sv) |
| DK (1) | DK0675956T3 (sv) |
| ES (1) | ES2193152T3 (sv) |
| FI (2) | FI114478B (sv) |
| IL (1) | IL108149A (sv) |
| IT (1) | IT1257184B (sv) |
| NO (1) | NO315800B1 (sv) |
| PT (1) | PT675956E (sv) |
| RU (1) | RU2177480C2 (sv) |
| UA (1) | UA46702C2 (sv) |
| WO (1) | WO1994014959A1 (sv) |
| ZA (1) | ZA939621B (sv) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3882943B2 (ja) * | 1996-04-24 | 2007-02-21 | アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ | 瘢痕形成剤としてのコンポーネントｂ |
| WO1998056810A2 (de) * | 1997-06-09 | 1998-12-17 | Forssmann Wolf Georg | Humanes protein lus-i, seine herstellung und verwendung |
| CA2336773C (en) * | 1998-07-09 | 2009-12-15 | Applied Research Systems Ars Holding N.V. | Component b as angiogenic agent in combination with human growth factors |
| US6962700B1 (en) * | 2000-09-13 | 2005-11-08 | Atopix Pharmaceuticals Corporation | Method of manufacturing immune globulin |
| JP4891065B2 (ja) * | 2003-04-16 | 2012-03-07 | メルク セローノ ソシエテ アノニム | Ｓｌｕｒｐ−１組成物及びその使用方法 |
| US7343581B2 (en) * | 2005-06-27 | 2008-03-11 | Tela Innovations, Inc. | Methods for creating primitive constructed standard cells |
| US7590968B1 (en) | 2006-03-01 | 2009-09-15 | Tela Innovations, Inc. | Methods for risk-informed chip layout generation |
| US7446352B2 (en) | 2006-03-09 | 2008-11-04 | Tela Innovations, Inc. | Dynamic array architecture |
| US9230910B2 (en) | 2006-03-09 | 2016-01-05 | Tela Innovations, Inc. | Oversized contacts and vias in layout defined by linearly constrained topology |
| US9009641B2 (en) | 2006-03-09 | 2015-04-14 | Tela Innovations, Inc. | Circuits with linear finfet structures |
| US9035359B2 (en) | 2006-03-09 | 2015-05-19 | Tela Innovations, Inc. | Semiconductor chip including region including linear-shaped conductive structures forming gate electrodes and having electrical connection areas arranged relative to inner region between transistors of different types and associated methods |
| US7932545B2 (en) | 2006-03-09 | 2011-04-26 | Tela Innovations, Inc. | Semiconductor device and associated layouts including gate electrode level region having arrangement of six linear conductive segments with side-to-side spacing less than 360 nanometers |
| US8247846B2 (en) | 2006-03-09 | 2012-08-21 | Tela Innovations, Inc. | Oversized contacts and vias in semiconductor chip defined by linearly constrained topology |
| US7943967B2 (en) | 2006-03-09 | 2011-05-17 | Tela Innovations, Inc. | Semiconductor device and associated layouts including diffusion contact placement restriction based on relation to linear conductive segments |
| US8225261B2 (en) | 2006-03-09 | 2012-07-17 | Tela Innovations, Inc. | Methods for defining contact grid in dynamic array architecture |
| US8839175B2 (en) | 2006-03-09 | 2014-09-16 | Tela Innovations, Inc. | Scalable meta-data objects |
| US8448102B2 (en) | 2006-03-09 | 2013-05-21 | Tela Innovations, Inc. | Optimizing layout of irregular structures in regular layout context |
| US7956421B2 (en) | 2008-03-13 | 2011-06-07 | Tela Innovations, Inc. | Cross-coupled transistor layouts in restricted gate level layout architecture |
| US7763534B2 (en) | 2007-10-26 | 2010-07-27 | Tela Innovations, Inc. | Methods, structures and designs for self-aligning local interconnects used in integrated circuits |
| US7917879B2 (en) * | 2007-08-02 | 2011-03-29 | Tela Innovations, Inc. | Semiconductor device with dynamic array section |
| US8225239B2 (en) | 2006-03-09 | 2012-07-17 | Tela Innovations, Inc. | Methods for defining and utilizing sub-resolution features in linear topology |
| US8653857B2 (en) | 2006-03-09 | 2014-02-18 | Tela Innovations, Inc. | Circuitry and layouts for XOR and XNOR logic |
| US8541879B2 (en) | 2007-12-13 | 2013-09-24 | Tela Innovations, Inc. | Super-self-aligned contacts and method for making the same |
| US9563733B2 (en) | 2009-05-06 | 2017-02-07 | Tela Innovations, Inc. | Cell circuit and layout with linear finfet structures |
| US8245180B2 (en) | 2006-03-09 | 2012-08-14 | Tela Innovations, Inc. | Methods for defining and using co-optimized nanopatterns for integrated circuit design and apparatus implementing same |
| US8658542B2 (en) | 2006-03-09 | 2014-02-25 | Tela Innovations, Inc. | Coarse grid design methods and structures |
| US7577049B1 (en) | 2006-08-08 | 2009-08-18 | Tela Innovations, Inc. | Speculative sense enable tuning apparatus and associated methods |
| US7979829B2 (en) * | 2007-02-20 | 2011-07-12 | Tela Innovations, Inc. | Integrated circuit cell library with cell-level process compensation technique (PCT) application and associated methods |
| US8286107B2 (en) | 2007-02-20 | 2012-10-09 | Tela Innovations, Inc. | Methods and systems for process compensation technique acceleration |
| US8667443B2 (en) | 2007-03-05 | 2014-03-04 | Tela Innovations, Inc. | Integrated circuit cell library for multiple patterning |
| EP2201035B1 (en) * | 2007-09-20 | 2015-06-17 | Commonwealth Scientific and Industrial Research Organisation | Novel avian cytokines and genetic sequences encoding same |
| BRPI0818039A2 (pt) * | 2007-10-15 | 2014-10-14 | Chugai Pharmaceutical Co Ltd | Método para produzir uma célula capaz de produção de alto rendimento de heteroproteínas. |
| US8453094B2 (en) | 2008-01-31 | 2013-05-28 | Tela Innovations, Inc. | Enforcement of semiconductor structure regularity for localized transistors and interconnect |
| US7939443B2 (en) | 2008-03-27 | 2011-05-10 | Tela Innovations, Inc. | Methods for multi-wire routing and apparatus implementing same |
| KR101761530B1 (ko) | 2008-07-16 | 2017-07-25 | 텔라 이노베이션스, 인코포레이티드 | 동적 어레이 아키텍쳐에서의 셀 페이징과 배치를 위한 방법 및 그 구현 |
| US9122832B2 (en) | 2008-08-01 | 2015-09-01 | Tela Innovations, Inc. | Methods for controlling microloading variation in semiconductor wafer layout and fabrication |
| GB0820631D0 (en) * | 2008-11-11 | 2008-12-17 | London School Hygiene & Tropical Medicine | Vectors |
| EP2239322A1 (en) * | 2009-04-07 | 2010-10-13 | Basf Se | Use of enzymes to reduce formaldehyde from formaldehyde-containing products |
| US8661392B2 (en) | 2009-10-13 | 2014-02-25 | Tela Innovations, Inc. | Methods for cell boundary encroachment and layouts implementing the Same |
| US9159627B2 (en) | 2010-11-12 | 2015-10-13 | Tela Innovations, Inc. | Methods for linewidth modification and apparatus implementing the same |
| EP2740485B1 (en) * | 2012-12-07 | 2018-10-31 | Brightpulse Holding LTD. | Protein slurp-1 for use in the treatment of ocular diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4359415A (en) * | 1981-06-03 | 1982-11-16 | University Of Tennessee Research Corporation | Isolation of an antineoplastic protein fraction and an antineoplastic peptide fraction from human urine |
| US4470970A (en) * | 1981-07-02 | 1984-09-11 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
| US5298604A (en) * | 1992-07-27 | 1994-03-29 | Sloane Nathan H | Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes |
-
1992
- 1992-12-22 IT ITRM920919A patent/IT1257184B/it active IP Right Grant
-
1993
- 1993-12-21 AU AU58335/94A patent/AU690093B2/en not_active Ceased
- 1993-12-21 JP JP6514813A patent/JP3025014B2/ja not_active Expired - Fee Related
- 1993-12-21 WO PCT/EP1993/003645 patent/WO1994014959A1/en active IP Right Grant
- 1993-12-21 KR KR1019950702407A patent/KR100193107B1/ko not_active IP Right Cessation
- 1993-12-21 AT AT94904167T patent/ATE236976T1/de not_active IP Right Cessation
- 1993-12-21 DE DE69332861T patent/DE69332861T2/de not_active Expired - Fee Related
- 1993-12-21 EP EP94904167A patent/EP0675956B1/en not_active Expired - Lifetime
- 1993-12-21 DK DK94904167T patent/DK0675956T3/da active
- 1993-12-21 US US08/448,561 patent/US5908827A/en not_active Expired - Fee Related
- 1993-12-21 PT PT94904167T patent/PT675956E/pt unknown
- 1993-12-21 UA UA95062918A patent/UA46702C2/uk unknown
- 1993-12-21 ES ES94904167T patent/ES2193152T3/es not_active Expired - Lifetime
- 1993-12-21 CA CA002151156A patent/CA2151156A1/en not_active Abandoned
- 1993-12-22 ZA ZA939621A patent/ZA939621B/xx unknown
- 1993-12-22 IL IL10814993A patent/IL108149A/xx not_active IP Right Cessation
- 1993-12-22 RU RU95113418/13A patent/RU2177480C2/ru not_active IP Right Cessation
-
1995
- 1995-06-21 NO NO19952494A patent/NO315800B1/no not_active IP Right Cessation
- 1995-06-21 FI FI953091A patent/FI114478B/sv active IP Right Grant
-
2004
- 2004-04-29 FI FI20040608A patent/FI116059B/sv active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU690093B2 (en) | 1998-04-23 |
| EP0675956B1 (en) | 2003-04-09 |
| IT1257184B (it) | 1996-01-10 |
| RU2177480C2 (ru) | 2001-12-27 |
| AU5833594A (en) | 1994-07-19 |
| EP0675956A1 (en) | 1995-10-11 |
| DE69332861D1 (de) | 2003-05-15 |
| KR950704486A (ko) | 1995-11-20 |
| NO952494D0 (no) | 1995-06-21 |
| NO952494L (no) | 1995-08-21 |
| KR100193107B1 (ko) | 1999-06-15 |
| IL108149A (en) | 2005-05-17 |
| JP3025014B2 (ja) | 2000-03-27 |
| WO1994014959A1 (en) | 1994-07-07 |
| ITRM920919A0 (it) | 1992-12-22 |
| UA46702C2 (uk) | 2002-06-17 |
| ES2193152T3 (es) | 2003-11-01 |
| NO315800B1 (no) | 2003-10-27 |
| IL108149A0 (en) | 1994-04-12 |
| DE69332861T2 (de) | 2004-01-29 |
| FI953091A (sv) | 1995-06-21 |
| ZA939621B (en) | 1995-06-22 |
| CA2151156A1 (en) | 1994-07-07 |
| ATE236976T1 (de) | 2003-04-15 |
| US5908827A (en) | 1999-06-01 |
| ITRM920919A1 (it) | 1994-06-22 |
| DK0675956T3 (da) | 2003-07-07 |
| FI953091A0 (sv) | 1995-06-21 |
| FI20040608A (sv) | 2004-04-29 |
| FI114478B (sv) | 2004-10-29 |
| JPH08509359A (ja) | 1996-10-08 |
| PT675956E (pt) | 2003-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI116059B (sv) | Analogiförfarande för framställning av ett rekombinantprotein kallat komponent B samt DNA-molekyl, expressionsvektor och värdcell | |
| AU758004B2 (en) | Extended cDNAs for secreted proteins | |
| US6312922B1 (en) | Complementary DNAs | |
| EP0468337A1 (en) | DNA coding for a human vasoconstrictive peptide and use thereof | |
| WO1999025825A2 (en) | EXTENDED cDNAs FOR SECRETED PROTEINS | |
| CA2251262C (en) | Nucleic acid encoding a nervous tissue sodium channel | |
| EP0421284A1 (en) | Human endothelin-3 cDNA and use thereof | |
| US5716816A (en) | Clones encoding mammalian ADP-ribosylarginine hydrolases | |
| AU2003204659B2 (en) | Extended cDNAs for secreted proteins | |
| JPH06504669A (ja) | ５−ＨＴ↓１↓ｘ−レセプター | |
| AU2006201603B2 (en) | Extended cDNAs for secreted proteins | |
| JPH03123487A (ja) | 新規ポリペプチドの製造法 | |
| WO2001038375A1 (fr) | Nouveau polypeptide, proteine a doigt de zinc 58 et polynucleotide codant pour ce polypeptide | |
| WO2002012320A1 (fr) | Nouveau polypeptide, proteine humaine 12 liee a tnfr/ngfr contenant un domaine de cytochrome c, et polynucleotide codant ce polypeptide | |
| EP1903111A2 (en) | Extended cDNAs for secreted proteins | |
| JPH09252777A (ja) | マウス肝癌細胞由来増殖因子 | |
| WO2001038370A1 (fr) | Nouvelle sous-unite 49 de l'activateur de transcription polypeptidique et polynucleotide codant ce polypeptide | |
| WO2001040297A1 (fr) | Nouveau polypeptide, proteine nucleaire de transition humaine 10 contenant un domaine de liaison atp/gtp, et polynucleotide codant pour ce polypeptide | |
| CA2010593A1 (en) | Production of novel polypeptide | |
| CA2135905A1 (en) | Serotonin receptor, preparation and use thereof | |
| WO2001046439A1 (fr) | Nouveau polypeptide, proteine dnaj humaine 39, et polynucleotide codant pour ce polypeptide | |
| WO2001064733A1 (fr) | Nouveau polypeptide, facteur humain 22 lie a la transcription inverse, et polynucleotide codant pour ce polypeptide | |
| AU2006202884A1 (en) | Extended cDNAs for secreted proteins | |
| WO2001055406A1 (fr) | Nouveau polypeptide, adn polymerase iii 18, et polynucleotide codant pour ce polypeptide | |
| WO2001030835A1 (fr) | Nouveau polypeptide, pogo transposase humaine 14, et polynucleotide codant pour ce polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 116059 Country of ref document: FI |
|
| PC | Transfer of assignment of patent |
Owner name: LABORATOIRES SERONO SA Free format text: LABORATOIRES SERONO SA |